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Background: Vesico-urethral function may be evaluated in humans and dogs by conventional urodynamic testing
(cystometry and urethral pressure profilometry) or by electromyography. These techniques are performed under
general anaesthesia in dogs. However, anaesthesia can depress bladder and urethral pressures and inhibit the
micturition reflex. The primary objective of this pilot study was to evaluate the use of telemetry for urodynamic
investigation in dogs. We also aimed to determine the applicability of telemetry to toxicologic studies by assessing
the repeatability of telemetric recordings.
Results: Conventional diuresis cystometry was performed in six continent adult female Beagle dogs prior to
surgical implantation of telemetric and electromyographic devices. In the first phase of the telemetric study,
continuous recordings were performed over 8 days and nights. Abdominal, intravesical and detrusor threshold
pressures (Pdet th), voided volume (Vv), urethral smooth muscle electrical activity and involuntary detrusor
contractions (IDC) were measured during the bladder filling phase and during micturition episodes.
Vv recorded during telemetry was significantly lower than bladder volume obtained by diuresis cystometry.
Repeatability of telemetric measurements was greater for observations recorded at night. IDC frequency and Pdet
th were both lower and Vv was higher at night compared to values recorded during daytime.
In the second phase of the telemetric study, phenylpropanolamine, oestriol, bethanechol, oxybutynin or duloxetine
were administered orally for 15 days. For each drug, continuous recordings were performed overnight for 12 hours
on days 0, 1, 8 and 15. Electromyographic urethral activity was significantly increased 8 days after oestriol or
duloxetine administration. No significant changes in bladder function were observed at any time point.
Conclusions: In dogs, the high repeatability of nocturnal telemetric recordings indicates that this technique could
provide more informative results for urologic research. Urethral smooth muscle electrical activity appears to be
modified by administration of drugs with urethral tropism. In this pilot telemetric study, bladder function was not
affected by oral administration of urological drugs at their recommended clinical dosages. Experimental studies,
(pharmacokinetic and pharmacodynamic) and clinical studies are warranted to further define the effects of these
drugs on vesico-urethral function in dogs.
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Table 1 Comparison of urodynamic values obtained
during diuresis cystometry and during telemetry
Cystometry Pth Vol
Diuresis cystometry 33.7 ± 2.9 432.5 ± 77.7a
Telemetry 40.1 ± 2.4 91.9 ± 6.1b
Pth = Bladder threshold pressure (mmHg); Vol = Bladder volume (mL)
corresponds to the volume of urine retrieved from the urinary bladder at the
time of the micturition reflex during diuresis cystometry, or corresponds to the
volume of urine voided during telemetric cystometry.
Data are expressed as LSMean ± SEM.
Data with different superscripts are significantly different (P < 0.05).
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Vesico-urethral function in humans and dogs is cur-
rently investigated by conventional urodynamic testing,
including cystometry and urethral pressure profilometry,
and by electromyography (EMG) [1,2]. These techniques
are useful to diagnose alterations in bladder and/or
urethral contractility [2] but are subject to several limita-
tions. In animals, urodynamic investigation requires gen-
eral anaesthesia that can depress bladder and urethral
pressures and inhibit the micturition reflex [3]. In
humans, poor correlation between clinical findings and
urodynamic investigations has been described [4].
Other urodynamic tests have been developed to pro-
vide more accurate data regarding lower urinary tract
function. Diuresis cystometry allows for a better ap-
proximation of the physiologic bladder filling state,
with high threshold volume, compliance and low
threshold pressure [5]. This technique permits detec-
tion of involuntary detrusor contractions (IDC) in dogs
with and without clinical signs of bladder dysfunction
[6,7]. In humans, ambulatory urodynamic monitoring
can be helpful as several micturition cycles may be
studied in multiple physiologic conditions [8], allowing
better detection of IDC compared to retrograde filling
cystometry [9,10].
Urodynamic telemetry conveys significant benefits for
urologic research and has been described in non-rodent
species (monkeys, pigs, ovine foetuses and dogs). Uro-
dynamic telemetry reduces stress to the animals, does not
require animal handling or chemical restraint and offers a
non-invasive technique for prolonged monitoring. The
telemetric equipment comprises an implantable transmit-
ter that measures pressures and biopotentials (EMG,
ECG) and sends data via radio waves to a receiver. The
data are then converted and analysed [11,12]. During re-
cordings, the animals are placed in metabolic cages to
measure urine production [12,13].
Telemetric recordings offer several advantages for
pharmacodynamic studies. The effect of a single admin-
istration of darifenacin on bladder function in dogs has
recently been investigated by telemetry [12]. However, to
date there are no reports of telemetric assessment of any
of the drugs currently used to treat urinary incontinence
or retention in veterinary medicine.
Therefore, the aims of this pilot study were to inves-
tigate vesico-urethral function in female beagle dogs
using telemetry. We aimed to measure detrusor pres-
sure to perform EMG procedures, and also to study
the effects of circadian rhythm on these parameters.
Data obtained from diuresis cystometry were compared
with data from urodynamic telemetric testing. The ef-
fects of oral administration of phenylpropanolamine
(PPA), oestriol, bethanechol, oxybutynin and duloxetine
were also investigated.Results
Complications
Flank seromas were observed in 5 dogs following im-
plantation of the telemetric device. These all resolved
spontaneously within several days. Four dog developed
bacterial cystitis over the course of the study. These dogs
were excluded from the study whilst receiving antibiotic
treatment (3 weeks) and were reintroduced following
negative urine culture. In one dog, the electronic module
stopped working six months after implantation due to a
blood clot at the level of the connection between the
pressure catheter and the electronic module. The im-
plant was successfully removed and replaced.
Comparison between diuresis cystometry and telemetry
The mean volume of urine recorded during diuresis
cystometry was significantly greater than the mean Vv
recorded during telemetric recordings (P = 0.027) (Table 1).
Comparison between day and night studies
For the filling phase, urodynamic measurements were
not different between day and night studies. Abdominal
and bladder pressures were significantly influenced by
the age, weight and activity of the dogs (P < 0.0001) and
activity level also has a significantly influence on detrusor
pressure (P = 0.0007). The frequency of micturition was
not significantly different between day and night record-
ings, but significant inter-individual differences were ob-
served (P < 0.0001) (Table 2).
When considering micturition episodes, a good repeat-
ability of Vv, Pth and Pdet th measurements as well as
higher Vv values (P = 0.0088) were observed during night
recordings (Figure 1). During day recordings, higher Pdet
th values (P = 0.0041) and significant variability of Vv
values (P = 0.014) were found.
IDC were recorded at a significantly higher frequency
during the day (P = 0.032) (Table 2).
No difference in urethral electrical activity was ob-
served between day and night recordings (Table 2).
Drug studies
Following oestriol and duloxetine administration, EMGi/
hour values were significantly increased on day 8 compared
Table 2 Frequency of micturition, involuntary detrusor




Frequency of micturition 2.3 ± 0.2 1.8 ± 0.2
IDC 4.06 ± 1.14a 2.3 ± 1.14b
EMGi/hour (mV sec) 0.02156 ± 0.0065 0.02106 ± 0.0065
EMGi/minute (mV sec)
Pre-micturition
0.5968 ± 0.092 0.5388 ± 0.099
EMGi/minute (mV sec)
Post-micturition
0.5979 ± 0.092 0.5883 ± 0.092
EMGi/hour = integrated EMG during the hour around the micturition episode.
EMGi/minute = integrated EMG during the minute preceding (Pre-micturition)
or following (Post-micturition) the micturition episode.
Data are expressed as LSMean ± SEM.
Data with different superscripts are significantly different (P < 0.05).
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(Table 3).
During the entire course of the study, no significant
effect of PPA, oestriol, oxybutynin, bethanechol and
duloxetine was observed on the urodynamic parameters,
the frequency of micturition or IDC, or the EMGi/mi-
nute values (Tables 4 and 5).
Discussion
The results of this study demonstrate that telemetry in
dogs can be a valuable tool in urologic research. Voided
volumes were found to be lower when measured by telem-
etry, compared to measures obtained during diuresis
cystometry. No change in threshold pressures was ob-
served. In humans, the International Continence Society
has defined different bladder capacities recorded during
filling cystometry. The cystometric capacity is the bladder
volume measured at the end of the filling cystometrogram














































Figure 1 Telemetric cystometry: comparison of urodynamic
values obtained during day and night recordings (LSMean ±
SEM). Vv = voided volume; Pth = bladder threshold pressure; Pdet
th = Detrusor threshold pressure; Pabd th = Abdominal threshold
pressure. For each parameter, different superscripts (a,b) indicate
significant difference (P < 0.05).maximum cystometric capacity is the volume at which the
patient states a strong desire to void. The maximum an-
aesthetic bladder capacity is the maximum volume to
which the bladder can be filled under deep anaesthesia
[14]. Functional bladder capacity is determined by the use
of a voiding diary [2]. We believe that data obtained by tel-
emetry in dogs may be used to derive values for functional
bladder capacity or maximum cystometric capacity, while
volumes obtained during diuresis cystometry could repre-
sent maximum anaesthetic bladder capacity. During con-
ventional cystometry, the bladder is filled in a non-
physiological way leading to variability especially if high
filling rates are used [15]. High filling rate can be associ-
ated with mechanical trauma to receptors, nerve endings
and cell junctions. Bladder wall damage may alter the
frequency of action potentials and provoke a decreased
desire to void until larger bladder volumes are reached
[5,16]. Although diuresis cystometry has been described as
a more “physiological” way to investigate bladder function
in dogs, it remains an artificial filling method, altering
urodynamics.
Repeatability was good for measurements obtained dur-
ing the night emphasizing the importance of physiological
circadian variations on urodynamic investigation. In an
earlier 24-hour telemetry study in dogs, McCafferty et al.
(2009) [12] described differences between bladder pres-
sure in the dark compared to hours of light. Bladder pres-
sure also varied during periods of enhanced locomotor
activity.
In the present study, in addition to the routinely
reported urodynamic parameters, detrusor pressure was
also investigated as it provides a more accurate evalu-
ation of bladder function. Detrusor pressure represents
the component of intravesical pressure created by active
and passive forces in the bladder wall without the influ-
ence of pressure from other abdominal sources [14]. In
this study detrusor pressure values were higher during
daytime than at night.
Voided volumes were also increased at night, supporting
previously reported results in rats and humans [17-19].
Circadian variations may not be solely dependent on the
diurnal variation in glomerular filtration rate and urine
production, but could also depend on a neural or bladder-
based mechanism that contributes to variations in bladder
capacity [17]. In this study, no difference in micturition
frequency was observed between days and nights. These
findings contradict previous results in experimental ani-
mals and humans. Increased urination frequency during
periods of dark has been described in rats [17] and a
higher micturition frequency has been described during
the day in healthy human beings [15]. Furosemide has
been used during a 24-hour telemetric study to increase
micturition frequency [12]. However, while furosemide in-
creased voiding frequency and volume per void, it caused
Table 3 Urethral EMG: evolution of the EMGi/hour values during the different drug administrations
Drugs EMGi/hour (mV sec)
Day 0 Day 1 Day 8 Day 15
Phenylpropanolamine 0.019 ± 0.004 0.015 ± 0.004 0.018 ± 0.004 0.020 ± 0.004
Oestriol 0.018 ± 0.004b 0.018 ± 0.004b 0.027 ± 0.004a 0.019 ± 0.004b
Oxybutynin 0.02 ± 0.005 0.02 ± 0.004 0.022 ± 0.005 0.016 ± 0.005
Bethanechol 0.016 ± 0.004 0.022 ± 0.004 0.017 ± 0.004 0.016 ± 0.004
Duloxetine 0.017 ± 0.004b 0.017 ± 0.006b 0.055 ± 0.005a 0.019 ± 0.005b
EMGi/hour = integrated EMG during the hour around the micturition episode.
Data are expressed as LSMean ± SEM.
Within each row, data with different superscripts are significantly different (P < 0.05).
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not to use furosemide in the present study to limit inter-
ference with physiological values. This approach may have
contributed to the lack of variation in micturition fre-
quency between nights and days.
IDC, without urine loss, were more frequently ob-
served during the day than during the night and were
not observed during diuresis cystometry. IDC frequency
was not affected by the administration of any of the
drugs tested. Detrusor instability/idiopathic detrusor
overactivity is characterized by involuntary detrusor con-
traction during the filling phase, may be spontaneous or
provoked and lacks a defined cause [14]. Compared to
human studies, the frequency of IDC here was lower,
probably because higher cut-off pressure values were
chosen. In a previous telemetric study in pigs, IDC were
only observed in pigs with partial bladder outlet obstruc-
tion [11]. The clinical relevance of IDC in our healthy
experimental dogs is questionable. IDC could reflect
physiological detrusor activity not detectable during con-
ventional filling cystometry due to bladder desensitisa-
tion [20]. Alternatively, IDC could reflect contact
between the pressure sensor and the bladder wall [21].
The higher frequency of IDC observed during the day
may reflect higher daytime activity or differences in the
dog’s positioning. Greater detrusor activity is detected in
humans if cystometry is performed in a standing or sit-
ting position [22].Table 4 Telemetric cystometry: evolution of detrusor pressure
administrations
Drugs Pdet th (mm Hg)
Day 0 Day 1 Day 8 Da
Phenylpropanolamine 31.9 ± 8.5 28.4 ± 8.2 28.2 ± 8.5 24.5
Oestriol 22.4 ± 6.9 25.7 ± 6.9 26.1 ± 7.2 26.1
Oxybutynin 26.6 ± 7.5 30.1 ± 6.3 25.7 ± 7.5 26.1
Bethanechol 26.9 ± 7.9 34.7 ± 7.6 21.91 ± 7.5 24.6
Duloxetine 30.3 ± 7.1 30.4 ± 7.9 30.1 ± 8.3 34.7
Pdet th = Detrusor threshold pressure (mmHg); Vv = Bladder voided volume (mL).
Data are expressed as LSMean ± SEM.To the authors’ knowledge, urethral smooth muscle
electrical activity has not previously been investigated
using needle electrodes in dogs. In female dogs, the
smooth urethral muscle is the preferred therapeutic
target for the medical treatment of urethral sphincter
mechanism incompetence (USMI) [23,24]. Despite the
known contribution of smooth muscle to the mainten-
ance of resting urethral tone, we did not observe any
variation in urethral smooth muscle electrical activity
during the first phase of the study. It is possible that the
contribution of urethral smooth muscle to resting ureth-
ral tone induces insufficient electrical activity to activate
the EMG equipment. Smooth muscle fibres are arranged
in a syncytium with poorly defined synapses. The sum-
mation of extracellular currents in smooth muscle is
more random with a smaller net potential, preventing
the formation of reproducible motor unit potentials [25].
Smooth muscle action potentials are calcium ion
dependent, while those in striated muscle depend on
transmembrane sodium ion currents. The extracellular
current in smooth muscle may be smaller because of the
relatively lower membrane expression of calcium chan-
nels compared to sodium channel expression in striated
muscle [26]. In women and rats, urethral smooth muscle
activity has been recorded using surface or needle elec-
trodes [25,27]. Needle electrodes are influenced by the
electrical activity within a mean distance from the tip of
0.5 mm allowing the recording of a single motor unitand voided volume during the different drug
Vv (mL)
y 15 Day 0 Day 1 Day 8 Day 15
± 9.1 101.4 ± 46.2 109.9 ± 43.2 112.2 ± 46.1 175.1 ± 50.1
± 7.1 139.2 ± 36.4 160.6 ± 35.9 141.19 ± 39.6 121.3 ± 38.3
± 7.3 64.9 ± 40.3 79.6 ± 31.8 55.9 ± 41.5 71.4 ± 40.2
± 6.7 84.2 ± 45.4 85.8 ± 42.8 83.9 ± 43.1 129.5 ± 40.9
± 7.9 119.5 ± 39.1 186.6 ± 45.6 141.7 ± 49.5 174.8 ± 45.7
Table 5 Urethral EMG: evolution of the EMGi/minute values during the different drug administrations
Drugs EMGi/minute: Pre-micturition (mV sec) EMGi/minute: Post-micturition (mV sec)
Day 0 Day 1 Day 8 Day 15 Day 0 Day 1 Day 8 Day 15
Phenylpropanolamine 0.55 ± 0.1 0.54 ± 0.1 0.82 ± 0.11 0.99 ± 0.12 0.60 ± 0.01 0.59 ± 0.1 0.62 ± 0.11 0.51 ± 0.12
Oestriol 0.49 ± 0.11 0.58 ± 0.1 0.81 ± 0.12 0.51 ± 0.11 0.51 ± 0.11 0.6 ± 0.11 0.64 ± 0.12 0.49 ± 0.11
Oxybutynin 0.57 ± 0.12 0.53 ± 0.10 0.46 ± 0.12 0.52 ± 0.11 0.50 ± 0.12 0.64 ± 0.10 0.55 ± 0.12 0.48 ± 0.11
Bethanechol 0.41 ± 0.12 0.62 ± 0.09 0.55 ± 0.11 0.57 ± 0.10 0.50 ± 0.12 0.67 ± 0.09 0.49 ± 0.11 0.49 ± 0.10
Duloxetine 0.45 ± 0.11 0.51 ± 0.11 0.54 ± 0.10 0.60 ± 0.11 0.47 ± 0.11 0.56 ± 0.11 0.49 ± 0.10 0.56 ± 0.11
EMGi/minute = integrated EMG during the minute preceding or following the micturition episode.
Data are expressed as LSMean ± SEM.
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of muscle activity [28].
PPA stimulates α-adrenergic receptors in the smooth
muscle of the bladder neck and proximal urethra by act-
ing as an indirect sympathomimetic amine [29-31]. It
also stimulates β1- and β2-adrenergic receptors by indu-
cing the release or inhibiting the reuptake of norepin-
ephrine [32-34]. In this study, no change in urethral
smooth muscle electrical activity was observed following
oral PPA administration. This finding contradicts previ-
ous work showing that PPA is effective in improving
urethral function in continent and incontinent bitches
[35-39]. After two weeks of PPA administration, a clear
trend towards decreased detrusor threshold pressure
and increased voided volume was observed. This finding
matches urodynamic changes observed previously in re-
sponse to a single oral administration of PPA at this
dose [40]. Overall, results from this study, though not
statistically significant, support the hypothesis that PPA
induces bladder relaxation by acting on β-adrenergic re-
ceptors in the bladder wall [41].
Various reviews in human medicine have summarized
the effects of oestrogens on the lower urinary tract and
their efficacy in the treatment of stress urinary incontin-
ence (SUI) in women [42-44] and USMI in bitches
[45,46]. However, evidence of clinical efficacy is lacking.
Oestrogens increase the number and responsiveness of α-
adrenergic receptors to sympathetic stimulation [25,47],
and increase blood flow to the urethral tissues [48]. They
stimulate cellular proliferation and improve the matur-
ation index of urethral epithelium [49]. Oestrogens may
act on β3-adrenergic receptors [50] and on muscarinic re-
ceptors though this remains unproven [47,51,52]. In the
present study, the electrical activity of urethral smooth
muscle was significantly increased after 8 days of oestriol
oral administration. This finding supports a previous
urodynamic study on anaesthetized dogs that reported a
significant increase in urethral pressure after 7 days of
daily administration of oestriol [46]. A stimulating effect
of oestrogens on the urethral smooth muscle may there-
fore be suspected.Bethanechol is a parasympathicomimetic drug indi-
cated for the treatment of urinary retention. However,
results of experimental studies in mice, cats and dogs
are inconclusive [53-55] and evaluations of its clinical ef-
ficacy in humans and dogs have been disappointing
[56-59]. The effects of bethanechol on bladder function
have not yet been thoroughly assessed in veterinary medi-
cine. In this study, 15 days of oral administration of
bethanechol at recommended clinical dosages caused no
change in urethral or bladder function. Further studies are
required to investigate the potential effect of bethanechol
at different dosages on vesico-urethral function.
Oxybutynin is a muscarinic receptor antagonist with
effects on the detrusor muscle [60]. It is commonly used
in human patients for the treatment of detrusor instabil-
ity [61-65] and its use has been reported in a dog and a
cat [66]. Previous experimental studies in rat and dog
models demonstrated an increased bladder volume with
decreased bladder contraction pressure after high doses
of oxybutynin [67], or an increased bladder volume
without variation of bladder pressure [68,69].
In this study, we did not observe any changes in bladder
function following oral administration of oxybutynin at
dosages extrapolated from human literature. McCafferty
et al. (2009) recently reported the effect of a single admin-
istration of darifenacin, a M3 receptor selective antagonist,
on telemetric urodynamics in dogs. The described de-
crease in peak micturition pressure could also be attrib-
uted to the administration of furosemide during the
experiment [12].
Duloxetine is a balanced serotonin-norepinephrine re-
uptake inhibitor acting at the presynaptic neurons in
Onuf ’s nucleus of the sacral spinal cord [70,71]. Though
duloxetine is commonly used in women with SUI [70,71],
reports of its use in dogs with bladder or urethral dysfunc-
tion are rare. Duloxetine amplifies the effect of glutamate
in Onuf ’s nucleus, increasing pudendal nerve activity.
Duloxetine also plays a role in initiating urethral striated
muscle contraction during bladder filling [72,73]. In
women with SUI, the clinical efficacy of duloxetine is
based on stronger urethral contraction and persistent
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study, after 8 days of oral administration of duloxetine, an
increase in urethral smooth muscle electrical activity was
recorded, while no change in bladder function was ob-
served. EMG studies of urethral smooth and striated
muscle are warranted in dogs to further investigate the
potential effects of duloxetine and its viability for the
treatment of dogs with refractory urinary incontinence.
The principal limitation of this pilot study is the small
number of dogs included. We tried to compensate for this
by using the telemetry tool to record multiple micturition
events per dog thereby maximising available data. Another
important limitation is the lack of a defined dose for each
drug; due to financial restrictions in this study, evaluations
of the drugs at a range of different doses was not per-
formed. With the exception of PPA [35], no studies have
been published comparing the pharmacokinetic and phar-
macodynamic properties of these drugs. The dosages were
chosen based on current recommendations in the veterin-
ary or human literature. Therefore, the results of this study
could reflect inappropriate drug levels. Further studies in-
volving oral and intravenous administration of these differ-
ent drugs at different dosages are warranted. The method
of EMG recordings could also affect the results; a system
composed of multiple electrodes may have been more ap-
propriate to detect the electrical signal when no drug was
present. Finally, the clinical status and breed of dog used in
this study may not be representative of the wider canine
population as these animals were all healthy female dogs
without any signs of urinary incontinence and with no pre-
disposition to developing micturition disorders.
Conclusions
Telemetry appears to be a useful investigative tool to ob-
tain physiological data on bladder function in dogs. The
results of this pilot study suggest that circadian varia-
tions may influence urodynamic measurements and that
long-term telemetric studies of the lower urinary tract
should be conducted during the night to obtain repeat-
able recordings. The investigation of urethral smooth
muscle function by EMG needle electrodes appears to
be a feasible method to study the effects of drugs with
urethral tropism. Further pharmacokinetic and pharma-
codynamics studies are needed to confirm the effects of
the different drugs on vesico-urethral function.
Methods
This study was approved by the Institutional Animal
Ethical Committee of the University of Liège (protocol
agreement #1084).
Dogs
Six adult entire female Beagle dogs were included in the
study. All dogs were healthy, in anoestrus and free oflower urinary tract disease. The mean age of the dogs
was 53.3 ± 17.1 months old (mean ± SD) and the mean
weight was 15.9 ± 1.5 kg (mean ± SD). They were housed
at the animal facilities of the Research Unit of the De-
partment of Clinical Sciences of the College of Veterin-
ary Medicine, University of Liège. Animal housing, care,
and experimentation were in accordance with Belgian
governmental regulations and with the NIH Guide for
Care and Use of Laboratory Animals.Part 1: Diuresis cystometry
Diuresis cystometry was performed in all 6 dogs under
general anaesthesia induced with an IV bolus of propofol
(Ecuphar, Belgium, 6 mg/kg) and maintained with an IV
infusion of propofol at a maximal dosage of 0.3 mg/kg/
min in order to maintain a light and stable depth of an-
aesthesia without need of tracheal intubation. Furosem-
ide (Intervet, Belgium, 5 mg/kg, IV) was administrated
prior to starting the IV administration of Lactated Ringer’s
solution (20 mL/kg/h). Dogs were placed in right lateral
recumbency and a 10-F triple lumen perfusion catheter
was inserted into the bladder via the external urethral me-
atus and positioned such that the urethral side-hole was
placed at the level of maximal urethral pressure. Bladder
and urethral pressures were recorded until micturition
was detected (Libra +Medical Measurement Systems,
Benetec, Belgium). At that moment, fluid was retrieved
from the bladder to measure the threshold volume, and
anaesthesia was discontinued [5].Part 2: Urodynamic telemetric investigation
Telemetry transmitters (Physio Tel Multiplus transmit-
ter TL11M3-D70-PCTP, DSI Data Science International,
USA) are designed to measure combinations of pres-
sure, biopotentials, temperature and activity. Transmit-
ters are composed of 2 biopotential leads and 2 fluid-
filled catheters with a thin-walled tip covered with an
antithrombogenic film and filled with noncompressable
fluid. Sensitive pressure changes are detected in the
thin-walled section of the catheter and transferred to
the pressure sensor located in the transmitter body. Re-
cordings are digitized in the electronic module and data
are wirelessly sent via radio frequency waves to a remote
receiver (RMC-1 Physio Tel, DSI Data Science Inter-
national, USA) placed in the lateral wall of a metabolic
cage with a maximal transmission distance of 1 cubic
meter. Signals are converted inside the data exchange
matrix (Dataquest ART Data Exchange Matrix, DSI
Data Science International, Sa USA). Data are trans-
ferred to a computer by an acquisition and analysis sys-
tem (Dataquest Acquisition and Analysis System ART,
DQ ART 3.1 Gold CM, DSI Data Science International,
USA).
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Transmitters were aseptically placed in all 6 dogs after
premedication with medetomidine (Eurovet, Nederlands,
15 μg/kg, IV). Anaesthesia was induced with propofol
(3 mg/kg, IV) and maintained with isoflurane (Ecuphar,
Belgium, 0.8–2%) delivered in 100% oxygen using a re-
breathing system. Dogs also received carprofen (Pfizer,
Belgium, 4 mg/kg, IV) and cefazolin (Sandoz, Belgium,
20 mg/kg, IV).
A ventral midline celiotomy was performed and the
transmitter body was secured subcutaneously to the left
abdominal wall. The leads of the transmitter were passed
into the abdominal cavity through the abdominal wall.
The extremity of the first pressure catheter was placed
into the bladder through a hole made in the ventral
bladder wall and was secured to the bladder wall with a
purse-string suture. The second pressure catheter was
left free in a caudal intraabdominal position. The 2 EMG
leads were placed into the smooth muscle part of the ur-
ethral wall (confirmed by histology of a biopsy speci-
men) at the level of the cranial third of the urethra, and
secured with simple interrupted sutures. The abdomen
was routinely closed. Postoperatively, the dogs received
buprenorphine (Ecuphar, Belgium, 15 μg/kg, IV, QID)
for 48 hours, carprofen (Pfizer, Belgium, 2 mg/kg, PO,
BID) for 4 days, and cefazolin (Intervet, Belgium, 20 mg/
kg, PO, BID) for 6 days.
Study protocol
Telemetric recording started one month after surgical
implantation to decrease the risk of detrusor instability
secondary to surgery. Dogs were placed in a metabolic
cage with a uroflowmetry system for urine collection.Figure 2 Telemetric recording. IDC = Involuntary detrusor contraction, MPrior to recording, each dog had a period of acclimatisa-
tion to the cage. During this period, completion of mic-
turition was confirmed by abdominal ultrasonography.
The telemetric study was divided into 2 phases: the first
phase included a day study and a night study, and the
second phase included the study of the 5 urological
drugs. The same 6 dogs were included in both phases.
First phase
To study the influence of circadian rhythym on vesico-
urethral function, the dogs were placed in the metabolic
cage in a lighted room and telemetric recordings were
performed continuously from 7 am to 7 pm for 8 days.
Upon completion of the day study, the dogs were placed
in the metabolic cage in a dark room and telemetric
recordings were performed continuously from 7 pm to
7 am for 8 nights.
Second phase
The immediate-release form of each drug was adminis-
tered orally for 15 days. Telemetric recordings were
performed in a dark room over night for 12 hours on
day 0 (before administration), and then on days 1, 8 and
15. A two-week washout period was respected between
each drug study.
The following doses of drugs were used: 1.5 mg/kg SID
for PPA (Vetoquinol, Belgium), 1 mg/dog SID for oestriol
(Intervet, Belgium), 12.5 mg/dog TID for bethanechol
(Merck Frosst, Canada), 3.75 mg/dog BID for oxybutynin
(Sanofi-Aventis, Belgium), and 20 mg/dog BID for
duloxetine (Eli Lilly, Netherlands).
Telemetric data were sampled at a frequency rate of
500 Hz and a moving average of 1 second was applied.=Micturition.
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recordings, the activity of the dogs was continuously
recorded by a surveillance camera (IP/Analog Surveillance
camera, Digitus, Duitsland). This camera is a network-
based digital surveillance device with a built-in web server
for the purpose of remote monitoring and recording.
Video surveillance of the dogs over IP network infrastruc-
ture was available at all times, on the author’s computer.
This closed-circuit camera system was set up and
synchronised with the telemetric program. This enabled
differentiation between micturition and IDC as only mic-
turition was associated with urine expulsion.
Data interpretation
The following variables were measured by diuresis
cystometry: threshold pressure (Pth, intravesical pressure
at the time of micturition reflex), threshold volume (Vth,
volume of fluid retrieved from the urinary bladder at
micturition reflex), and compliance (C). Compliance was
calculated by use of the following equation: C = (Vth –
V0)/ (Pth – P0), where V0 and P0 are the intravesical
volume and pressure, at the start of cystometric evalu-
ation. These definitions are in accordance with those of
the International Continence Society [14].
The following variables were measured or calculated
from continuous telemetric recordings of the filling
phases: abdominal pressure, bladder pressure and detrusor
pressure (Detrusor P: bladder pressure – abdominal pres-
sure). The data were averaged over 15 minutes periods.
The following variables were measured or calculated
from telemetric recordings taken at the time of the mic-
turition reflex: threshold bladder pressure (Pth), voided
volume (Vv) and threshold abdominal pressure. The
threshold detrusor pressure (Pdet th) was calculated by
use of the following equation: Pdet th = Pth – Pabd th.
IDC were recorded throughout telemetric recordings
and were defined as a rapid involuntary pressure in-
crease of ≥ 15 cmH2O occurring during the filling phase
at a lower threshold volume than would be expected to
provoke a normal micturition reflex (Figure 2) [76].
The electrical activity of the urethral smooth muscle
was studied during the hour around each micturition
episode. EMG signals were filtered from 2 to 40 Hz and
were analysed by calculating the EMG integral activity
(EMGi) over 2 seconds. EMGi values were obtained
30 minutes, 5 minutes, 1 minute and 10 seconds before
the micturition episode, at the time of micturition, and
10 seconds, 1 minute, 5 minutes and 30 minutes after
the end of micturition. The global smooth muscle activ-
ity during the hour around the micturition episode
(EMGi/hour) was measured by taking the mean of these
different EMGi values.
The electrical activity of the urethral smooth muscle was
also analysed during the minute immediately preceding themicturition episode and immediately following the mictur-
ition episode. The EMGi value (EMGi/minute) was calcu-
lated over 60 seconds.
Statistical analysis
Data were expressed as Least Square Mean (LSMean) ±
SEM. Urodynamic data obtained by diuresis cystometry
and telemetric investigation were analysed and com-
pared using the GLM procedure (SAS/STAT software,
version SAS (1) 9.1 (TS1M3) on Linux 2.4.21-50, ELsmp
platform, SAS Institute Inc, Cary, NC). The frequency of
micturition during the first phase of the telemetric study
was analysed and compared by the LOGISTIC proced-
ure of the SAS software, in agreement with the discreet
character of this variable. The MIXED procedure of the
SAS software was used to analyse and compare the
urodynamic and electromyographic data obtained during
the day and night studies, as well as during the adminis-
tration of PPA, oestriol, bethanechol, oxybutynin and
duloxetine. These statistical models take into account
the possible correlations between successive measures
over time. A value of P < 0.05 was considered significant.
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